When designing chimeric antigen receptor (CAR)-based therapies, regulatory T cells (Tregs) can be targeted to specific, desired antigens to create immune tolerance. Manipulating these cells offers the opportunity to treat organ transplant rejection and autoimmune diseases. However, the use of polyclonal Tregs with uncharacterized antigen specificities has led to undesirable effects, so the accurate profiling and characterization of these engineered immune cells is critical. In this GEN webinar, we will learn how single-cell functional proteomics is crucial in the informed design and development of the next generation of cell therapies. More importantly, we will hear how using single-cell cytokine expression can be used to functionally profile CAR-Tregs.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.